Friday, November 20, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 61

Roche's Oral Breast Cancer Pill Giredestrant Lands FDA Approval

The FDA has cleared Roche's Wilserdly (giredestrant), an oral drug for advanced breast cancer that has stopped responding to hormone therapy. In a phase III trial it cut the risk of disease progression or death by 62%. India is watching — but the drug needs its own regulatory green light first.

By the Paparazzi desk November 20, 2026 · 4:01 AM · outlookindia.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: outlookindia.com.
  • The source published it on Nov 20, 2026 at 4:01 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

Roche now has US Food and Drug Administration approval for Wilserdly (giredestrant), an oral treatment given alongside everolimus. The green light covers adults with oestrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease no longer responds to hormone-based therapy. It targets a group of patients who typically run short of options once existing treatments stop working.

The headline number comes from the global phase III evERA trial. In patients whose tumours carried ESR1 mutations, the giredestrant combination reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus. That matters because ESR1 mutations are estimated to show up in up to 40% of people with hormone receptor-positive metastatic breast cancer, and they are a leading reason hormone treatments eventually fail.

Sponsored

Giredestrant is an oral selective oestrogen receptor degrader (SERD): it blocks the oestrogen receptor and triggers its breakdown, cutting off signals that feed certain breast cancer cells. Everolimus attacks a separate growth pathway, so the pair hits two mechanisms behind tumour progression and resistance. The pill form means patients can take treatment at home instead of scheduling injections, though medical supervision, monitoring and side-effect management are still required.

India is not covered by the US decision. Wilserdly will need its own Indian regulatory clearances before it can be marketed there for this use, and how far it spreads will hinge on price, the availability of ESR1 mutation testing and access to specialist oncology services. Breast cancer is the most common cancer among Indian women, with nearly 2.39 lakh new cases projected for 2025 by the National Cancer Registry Programme. For families already stretched by advanced cancer costs, affordability could decide everything.

One caveat: this is not a cure. The trial showed a significant delay in disease progression, not proof that the treatment wipes out the disease or extends overall survival. Roche is also waiting on a separate FDA ruling for giredestrant as an adjuvant therapy in early-stage ER-positive, HER2-negative breast cancer, with a decision expected by November 30, 2026 — a verdict that would push the drug into post-surgery care aimed at keeping cancer from returning.

TopicsRoche · giredestrant · Wilserdly · FDA · everolimus · India's National Cancer Registry Programme · ESR1

Share

Source: outlookindia.com

Written by AI from verified reporting.

More stories

  • Health & science 19:52 UTC · 58 minutes ago · medicalxpress.com · Caught by @ajayy30 · 0 views
    Guinea Pig Ears Upend the Nobel-Winning Map of How We Hear
  • Health & science 19:50 UTC · 1 hour ago · phys.org · Caught by @ajayy30 · 0 views
    Lopsided galaxies are shaped from within, catalog of 606 suggests
  • Health & science 19:48 UTC · 1 hour ago · sciencedaily.com · Caught by @ajayy30 · 0 views
    Moon dust 3D-printed into LEGO-style bricks for future lunar bases
  • Health & science 18:01 UTC · 3 hours ago · medtechdive.com · 1 view
    Zimmer files FDA 510(k) for Monogram knee robot, eyes 2027 launch
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.